PHARMACY

Report: Some branded diabetes drug prices at Walmart, Kmart rise at fast rate

BY Alaric DeArment

NEW YORK — Prices for the top 10 most prescribed branded diabetes drugs have risen faster at Walmart and Kmart than at other retailers, according to a published report.

Citing a recent study by researchers at the Mount Sinai Medical Center in New York, Reuters reported that Walmart raised prices for branded diabetes drugs by 32% between 2008 and 2010, compared with 21% for the industry as a whole — including independent and chain retail pharmacies and mail-order companies. Kmart raised prices by 35%.

Walmart has long been considered an innovator for its $4 generics program, introduced in 2006, which since has become almost standard practice for retailers around the country. The study also found that generic drug prices fell by 58% over the two-year period, while branded drug prices increased by 113%.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Novo Nordisk’s Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin

BY Allison Cerra

SAN DIEGO — Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

The drug maker found that combining Victoza (liraglutide [rDNA origin] injection) with metformin and/or sulfonylurea helped patients achieve blood-sugar control.

Additionally, Novo Nordisk also presented data that showed that the addition of Levemir (insulin detemir [rDNA origin] injection) to Victoza and metformin helped patients reach and maintain blood sugar targets. The results also showed a low frequency of hypoglycemia and maintained weight loss among patients.

Both switch trials were extensions of randomized, open-label studies that compared the efficacy and safety of Victoza in 1.2-mg and/or 1.8-mg strengths, taken once daily, with twice-daily exenatide (10 μg) or sitagliptin (100 mg), all in combination with metformin and/or sulfonylurea.

“The results … are encouraging. Not only did Victoza treatment alone help more than 60% of patients achieve the ADA target for blood-sugar control, but also the addition of Levemir helped many of the remaining patients achieve the ADA target without the increases in hypoglycemia and body weight normally associated with insulin therapy,” Novo Nordisk EVP and chief science officer Mads Krogsgaard Thomsen said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Garamycin ophthalmic solution enters market

BY Allison Cerra

NEW YORK — Fera Pharmaceuticals has launched an ocular bacterial infections treatment.

The company announced the launch of Garamycin (gentamicin sulfate) ophthalmic solution USP, designed to treat such infections as conjunctivitis, keratitis and blepharitis.

Last year, Fera broadened its Garamycin product offerings with the launch of preservative-free Garamycin ophthalmic ointment.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?